{"id":"W4389503869","doi":"10.1016/j.annonc.2023.10.123","title":"Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Sanofi Genzyme; Genentech; Castle Biosciences; Incyte; Array BioPharma; Regeneron Pharmaceuticals; Sanofi; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Interquartile range; Clinical endpoint; Internal medicine; Gastroenterology; Phases of clinical research; Progression-free survival; Surgery; Oncology; Toxicity; Adverse effect; Overall survival; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004608992,0.001118855,0.001902932,0.0003637875,0.0003413194,0.001383689,0.0006870748,0.0009951091,0.002814178],"category_scores_gemma":[0.002431183,0.0003823047,0.001851946,0.0003723792,0.0004630201,0.0005308092,0.0003948369,0.002835061,0.0008281415],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001058684,"about_ca_system_score_gemma":0.001649198,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004719632,"about_ca_topic_score_gemma":0.001170623,"domain_scores_codex":[0.9987902,0.0006546606,0.00008581793,0.0001287887,0.0001309188,0.0002095076],"domain_scores_gemma":[0.9979336,0.0004579833,0.000440413,0.0001936904,0.0002944527,0.0006798689],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6147841,0.03631657,0.02460155,0.001866948,0.005275657,0.0005760815,0.0005137842,0.01008413,0.1380349,0.0004897129,0.01669587,0.1507606],"study_design_scores_gemma":[0.2499926,0.649988,0.05118134,0.0001566416,0.002865845,0.001089692,0.0001371787,0.003506405,0.02472988,0.0005547669,0.01572502,0.00007266922],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980608,0.004572635,0.00216134,0.0006264902,0.0001716049,0.004365582,0.00466407,0.000198137,0.002632194],"genre_scores_gemma":[0.9752769,0.001483962,0.003942233,0.001025107,0.0001490752,0.003123392,0.01245754,0.00008752918,0.002454343],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004608992,"threshold_uncertainty_score":0.02437496,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07055745788880101,"score_gpt":0.3505858826284589,"score_spread":0.2800284247396578,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}